WO2000042989A2 - Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules - Google Patents
Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules Download PDFInfo
- Publication number
- WO2000042989A2 WO2000042989A2 PCT/US2000/001684 US0001684W WO0042989A2 WO 2000042989 A2 WO2000042989 A2 WO 2000042989A2 US 0001684 W US0001684 W US 0001684W WO 0042989 A2 WO0042989 A2 WO 0042989A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cochleates
- suspension
- lipid
- polymer
- biologically relevant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Definitions
- the present invention relates to a novel process for preparing a novel lipid-based cochleate delivery system, the pharmaceutical preparations derived from the lipid-based cochleate delivery system, and the use of these pharmaceutical preparations to achieve efficient systemic and mucosal delivery of biologically relevant molecules.
- biologically relevant molecules to be administered via the oral route depends on several factors.
- the biologically relevant molecule must be soluble in the gastrointestinal fluids in order for the biologically relevant molecule to be transported across biological membranes for an active transport mechanism, or have suitable small particle size that can be absorbed through the Peyer's Patches in the small intestine and through the lymphatic system. Particle size is an important parameter when oral delivery is to be achieved (see Couvreur P. et al, Adv. Drug Delivery Reviews 10:141-162, 1993).
- the primary issue in the ability to deliver drugs orally is the protection of the drug from proteolytic enzymes.
- An ideal approach is to incorporate the drug in a hydrophobic material so that the aqueous fluids cannot penetrate the system.
- Lipid-based cochleates are an ideal system that can achieve this purpose.
- cochleates have a nonaqueous structure and therefore they:
- a) are more stable because of less oxidation of lipids; b) can be stored lyophilized, which provides the potential to be stored for long periods of time at room temperatures, which would be advantageous for worldwide shipping and storage prior to administration;
- f have a lipid bilayer which serves as a carrier and is composed of simple lipids which are found in animal and plant cell membranes, so that the lipids are non- toxic;
- h can be produced as defined formulations composed of predetermined amounts and ratios of drugs or antigens.
- Cochleate structures have been prepared first by D. Papahadjopoulos as an intermediate in the preparation of large unilamellar vesicles (see US 4,078,052).
- the use of cochleates to deliver protein or peptide molecules for vaccines has been disclosed in US
- the method further comprises the steps required to encochleate at least one biologically relevant molecule in the hydrogel-isolated cochleates in a therapeutically effective amount.
- a "biologically relevant molecule” is one that has a role in the life processes of a living organism.
- the molecule may be organic or inorganic, a monomer or a polymer, endogenous to a host organism or not, naturally occurring or synthesized in vitro, and the like.
- examples include vitamins, minerals, amino acids, toxins, microbicides, microbistats, co-factors, enzymes, polypeptides, polypeptide aggregates, polynucleotides, lipids, carbohydrates, nucleotides, starches, pigments, fatty acids, hormones, cytokines, viruses, organelles, steroids and other multi-ring structures, saccharides, metals, metabolic poisons, drugs, and the like.
- the particle size of the encochleated biologically relevant molecule is less than one micron, and further wherein the biologically relevant molecule is preferably a drug.
- the present invention further provides a method of orally administering to a host a biologically effective amount of the above-described cochleate.
- the biologically relevant molecule-cochleate is administered orally.
- FIG. 1 Schematic of the process by which the hydrogel-isolated cochleates with or without drug are obtained.
- FIGS. 2a and 2b Particle size distribution (weight analysis) of hydrogel isolated cochleates either loaded with amphotericin B (AmB) (fig 2a) or empty (fig 2b) as measured by laser light scattering.
- AmB amphotericin B
- fig 2a fig 2a
- empty fig 2b
- FIGs 3a and 3b Microscopic images of a mixture of liposomes in dextran dispersed into PEG gel solution.
- the small black dots are dextran particles formed by dispersing the dextran phase in the PEG phase.
- the large open circles are formed by fusion of small dextran particles. Partition of liposomes favors the dextran phase as indicated by the yellow color of AmB.
- 3b Microscopic images of the sample shown in Fig. 3a after treatment with CaCl 2 solution.
- the black objects in circles, indicated by an arrow, are cochleates formed by the addition of Ca 2+ ions.
- FIGS. 4a-4f Microscopic images of the sample shown in Figs. 3a and 3b after washing with a buffer containing 1 mM CaCl 2 and 100 mM NaCl. Aggregates are formed by the Cochleate particles.
- 4b Suspension shown in Fig. 4a following the addition of EDTA. Cochleate particles opened to liposomes with a diameter of 1-2 microns, indicating the intrinsic size of the cochleate particles is in sub-micron range.
- 4c AmB hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 4.
- 4d Cochleates displayed in fig 4c after treatment with EDTA.
- 4e Empty hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 3.
- 4f cochleates displayed in 4f after treatment with EDTA.
- FIG. 1 Micrographs of hydrogel-isolated cochleates after freeze fracture.
- AmB at 0.625 ⁇ g AmB/ml. Comparison is made to AmB in DMSO and AmBisome R .
- FIG. 7 Effect of hydrogel-isolated cochleates on the viability of Candida albicans after 30 hours.
- Figure 10 Time profile tissue concentration of AmB after single dose administration of hydrogel-isolated cochleates loaded with AmB.
- the present invention provides a solution to achieve effective oral delivery of drugs by producing small-sized cochleates using a new process.
- the new approach is based on the incompatibility between two polymer solutions, both of which are aqueous.
- Aqueous two- phase systems of polymers are well used for protein purification due to a number of advantages such as freedom from the need for organic solvents, mild surface tension and the biocompatibility of aqueous polymers (see P.A. Albertsson in "Partition of cell particles and macromolecules", 3 rd edition, Wiley NY 1986; and "Separation using aqueous Phase System” D. Fisher Eds, Plenum NY, 1989).
- processes for preparing small- sized, lipid-based cochleate particles and preparations derived therefrom comprising a biologically relevant molecule incorporated into the particles.
- the cochleate particles are formed of an alternating sequence of lipid bilayers/cation.
- the biologically relevant molecule is incorporated either in the lipid bilayers or in the interspace between the lipid bilayers.
- One of the processes for preparing the small-sized cochleates comprises: 1) preparing a suspension of small unilamellar liposomes or biologically relevant molecule-loaded liposomes, 2) mixing the liposome suspension with polymer A, 3) adding, preferably by injection, the liposome/Polymer A suspension into another polymer B in which polymer A is nonmiscible, leading to an aqueous two-phase system of polymers, 4) adding a solution of cation salt to the two-phase system of step 3, such that the cation diffuses into polymer B and then into the particles comprised of liposome/polymer A allowing the formation of small- sized cochleates, 5) washing the polymers out and resuspending the empty or drug-loaded cochleates into a physiological buffer or any appropriate pharmaceutical vehicle.
- a second process for preparing the small-sized cochleates comprises detergent and a biologically relevant molecule and cation.
- the process comprises the following steps:
- a lyophilization procedure can be applied and the lyophilized biologically relevant molecule-cochleate complex can be filled into soft or hard gelatin capsules, tablets or other dosage form, for systemic, dermal or mucosal delivery.
- the biologically relevant molecule partitions into either or both lipid bilayers and interspace, and the biologically relevant molecule is released from the cochleate particles by dissociation of the particles in vivo.
- Alternative routes of administration may be systemic such as intramuscular, subcutaneous or intravenous or mucosal such as intranasal, intraocular, intravaginal, intraanal, parenteral or intrapulmonary. Appropriate dosages are determinable by, for example, dose-response experiments in laboratory animals or in clinical trials and taking into account body weight of the patient, absorption rate, half-life, disease severity and the like. The number of doses, daily dosage and course of treatment may vary from individual to individual. Other delivery routes can be dermal, transdermal or intradermal.
- the first step of the new process of the present invention which is the preparation of small liposomes, can be achieved by standard methods such as sonication or microfluidization or other related methods (see for example Liposome Technology, Liposome Preparation and Related Techniques, Edited by Gregory Gregoriadis, Vol I, 2nd Edition, CRC Press, 1993).
- polymer A/liposome suspension into polymer B can be achieved mechanically by using a syringe pump at an appropriate controlled rate, for example a rate of 0.1 ml/min to 50 ml/min and preferably at a rate of 1 to 10 ml/min.
- the lipids of the present invention are non-toxic lipids and include, but are not limited to simple lipids which are found in animal and plant cell membranes.
- the lipid is a negatively charged lipid, more preferably a negatively charged phospholipid, and even more preferably a lipid from the group of phosphatidylserine, phosphatidylinositol, phosphatidic acid, and phosphatidyl glycerol.
- the lipids may also include minor amounts of zwitterionic lipids, cationic lipids or neutral lipids capable of forming hydrogen bonds to a biologically relevant molecule such as PEGylated lipid.
- the polymers A and B of the present invention can be of any biocompatible polymer classes that can produce an aqueous two-phase system.
- polymer A can be, but is not limited to, dextran 200,000-500,000, Polyethylene glycol (PEG) 3,400-8,000
- polymer B can be, but is not limited to, polyvinylpyrrolidone (PNP), polyvinylalcohol (PVA), Ficoll 30,000-50,000, polyvinyl methyl ether (PNMB) 60,000-160,000, PEG 3,400-8,000.
- concentration of polymer A can range from between 2-20% w/w as the final concentration depending on the nature of the polymer. The same concentration range can be applied for polymer B.
- Dextran/PEG 5-20% w/w Dextran 200,000-500,000 in 4-10% w/w PEG 3,400-8,000
- PEG/PVME 2-10% w/w PEG 3,500- 35,000 in 6-15% w/w PVME 60,000-160,000.
- the biologically relevant molecule may be an organic molecule that is hydrophobic in aqueous media.
- the biologically relevant molecule may be a drug, and the drug may be an antiviral, an anesthetic, an anti-infectious, an antifungal, an anticancer, an immunosuppressant, a steroidal anti-inflammatory, a non-steroidal anti-inflammatory, a tranquilizer or a vasodilatory agent.
- Examples include Amphotericin B, acyclovir, adriamycin, cabamazepine, melphalan, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids rapamycin, propanidid, propofol, alphadione, echinomycine, miconazole nitrate, teniposide, taxol, and taxotere.
- the biologically relevant molecule may be a polypeptide such as cyclosporin, angiotensin 1, II and III, enkephalins and their analogs, ACTH, anti-inflammatory peptides I,
- bradykinin calcitonin
- b-endorphin dinorphin
- leucokinin leutinizing hormone releasing hormone (LHRH)
- insulin neurokinins
- somatostatin substance P
- TRH thyroid releasing hormone
- the biologically relevant molecule may be an antigen, but the antigen is not limited to a protein antigen.
- the antigen can also be a carbohydrate or a polynucleotide such as DNA.
- antigenic proteins examples include envelope glycoproteins from influenza or Sendai viruses, animal cell membrane proteins, plant cell membrane proteins, bacterial membrane proteins and parasitic membrane protein.
- the biologically relevant molecule is extracted from the source particle, cell, tissue, or organism by known methods. Biological activity of biologically relevant molecules need not be maintained. However, in some instances (e.g., where a protein has membrane fusion or ligand binding activity or a complex conformation which is recognized by the immune system), it is desirable to maintain the biological activity. In these instances, an extraction buffer containing a detergent which does not destroy the biological activity of the membrane protein is used. Suitable detergents include ionic detergents such as cholate salts, deoxycholate salts and the like or heterogeneous polyoxyethylene detergents such as Tween, BRIG or Triton.
- Utilization of this method allows reconstitution of antigens, more specifically proteins, into the liposomes with retention of biological activities, and eventually efficient association with the cochleates. This avoids organic solvents, sonication, or extreme pH, temperature, or pressure all of which may have an adverse effect upon efficient reconstitution of the antigen in a biologically active form.
- Hydrogel-isolated cochleates may contain a combination of various biologically relevant molecules as appropriate.
- the formation of small-sized cochleates is achieved by adding a positively charged molecule to the aqueous two-phase polymer solution containing liposomes.
- the positively charged molecule can be a polyvalent cation and more specifically, any divalent cation that can induce the formation of a cochleate.
- the divalent cations include Ca ++ , Zn ++ , Ba ++ and Mg "1-1" or other elements capable of forming divalent ions or other structures having multiple positive charges capable of chelating and bridging negatively charged lipids.
- Addition of positively charged molecules to liposome-containing solutions is also used to precipitate cochleates from the aqueous solution.
- cochleate precipitates are repeatedly washed with a buffer containing a positively charged molecule, and more preferably, a divalent cation. Addition of a positively charged molecule to the wash buffer ensures that the cochleate structures are maintained throughout the wash step ; and that they remain as precipitates.
- the medium in which the cochleates are suspended can contain salt such as calcium chloride, zinc chloride, cobalt chloride, sodium chloride, sodium sulfate, potassium sulfate, ammonium sulfate, magnesium sulfate and sodium carbonate.
- the medium can contain polymers such as Tween 80 or BRIG or Triton.
- the biologically relevant molecule-cochleate is made by diluting into an appropriate biologically acceptable carrier (e.g., a divalent cation- containing buffer).
- the cochleate particles can be enteric.
- the cochleate particles can be placed within gelatin capsules and the capsule can be enteric coated.
- hydrophobic materials can be added to provide enhanced absorption properties for oral delivery of biologically relevant molecules. These materials are preferably selected from the group consisting of long chain carboxylic acids, long chain carboxylic acid esters, long chain carboxylic acid alcohols and mixtures thereof.
- the hydrophobic materials can be added either initially to the lipid prior to the formation of liposomes or in a later step in the form of a fat vehicle such as an emulsion.
- Step 1 Preparation of small unilamellar vesicles from dioleoylphosphatidylserine.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Example 2 Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatidylserine and 1 ,2-Distearoyl-sn-glycerol-3-phosphoethanolamine-n- (polyethylene glycol)-5000, DSPE-PEG) precipitated with calcium
- Step 1 Preparation of small unilamellar vesicles.
- DOPS dioleoylphosphatidylserine
- the dried lipid film was hydrated with de-ionized water to a concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator (Laboratory Supplies Com., Inc.). Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast optical microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Example 3 Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatidylserine and n-octyl-beta-D-gluco-pyranoside precipitated with calcium
- Step 1 Preparation of small unilamellar vesicles.
- DOPS dioleoylphosphatidylserine
- the dried lipid film was hydrated with a solution of n-octyl-beta-D- gluco-pyranoside (OCG) at 1 mg/ml at a ratio of DOPS : OCG of 10: 1 w:w.
- OCG n-octyl-beta-D- gluco-pyranoside
- step 1 The suspension obtained in step 1 was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected via a syringe into
- Step 1 Preparation of small unilamellar AmB-loaded, vesicles from dioleoylphosphatidylserine.
- a mixture of dioleoyl phosphatidylserine (DOPS) in chloroform (10 mg/ml) and AmB in methanol (0.5mg/ml) at a molar ratio of 10: 1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 40 °C. The rotavapor was sterilized by flashing
- DOPS dioleoyl phosphatidylserine
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear yellow (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step :1 Preparation of small unilamellar DXR-loaded vesicles from dioleoylphosphatidylserine.
- DOPS dioleoylphosphatidylserine
- the dried lipid film was hydrated with de-ionized water at the concentration of 25 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear pink (suspension A) and there were no liposomes apparently visible under phase contrast microscope with a 1000X magnification.
- step 1 5 ml of the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-500,000 (Sigma) in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A CaCl solution (100 mM) was added to the suspension to reach the final concentration of ImM.
- Step 1 Preparation of small unilamellar CSPA-loaded vesicles from dioleoylphosphatidylserine.
- a mixture of dioleoylphosphatidylserine (DOPS) in chloroform (10 mg/ml) and CSPA in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at room temperature. The rotavapor was
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar NVIR-loaded vesicles from dioleoylphosphatidylserine.
- a mixture of dioleoylphosphatidylserine (DOPS) in chloroform (10 mg/ml) and ⁇ NIR in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by flashing
- DOPS dioleoylphosphatidylserine
- Step 2 Preparation of NVIR-loaded, hydrogel isolated, cochleates
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar RIF-loaded vesicles from dioleoylphosphatidylserine.
- DOPS dioleoylphosphatidylserine
- lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar Vitamin A-loaded vesicles from dioleoylphosphatidylserine.
- Vitamin A (retinol) is sensitive to air oxidation and is inactivated by UV light. Vitamin A is protected when embedded into lipid bilayers. The inco ⁇ oration is achieved as follows :
- DOPS dioleoylphosphatidylserine
- Vitamin A in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by
- Step 2 Preparation of Vitamin A-loaded, hydrogel isolated, cochleates
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran- 500,000 in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 ⁇ m. A CaCl solution (100 mM) was added to the suspension to reach the final concentration of ImM. Stirring was continued for one hour, then a washing buffer containing 1 mM CaCl 2 and 150 mM NaCl was added to suspension B at the volumetric ratio of 1 :1. The suspension
- PFA's are biologically relevant molecules involved in the control of the level of cholesterol in blood and are the precursors of prostaglandins. PFA's are sensitive to oxidation which limits their inco ⁇ oration in food. PFA's undergo, in the presence of oxygen, a series of reactions called autoxidation, leading to aldehydes then ketones. which has a fishy unpleasaant odor and flavor. Embedding PFA in rigid, enrolled, lipid bilayers help preventing the autoxidation cascade.
- a general method of preparing PFA- cochleates is as follows :
- Step 1 Preparation of small unilamellar PF A-loaded vesicles from dioleoylphosphatidylserine.
- a mixture of dioleoylphosphatidylserine in chloroform (10 mg/ml) and PFA in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a rotary evaporator at RT.
- the rotary evaporator was sterilized by flashing
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- Step 2 Preparation of PF A-loaded, hydrogel isolated, cochleates
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar CinO-loaded vesicles from dioleoylphosphatidylserine.
- CinO in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and
- the following steps were carried out in a sterile hood.
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar DNA-loaded vesicles from dioleoylphosphatidylserine.
- the dried lipid film was hydrated with a solution of pCMV-beta-gal- DNA in TE buffer (at 1 mg/ml) to reach a concentration of DOPS:DNA of 10:1 and a concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then vortexed for several minutes.
- Step 2 Preparation of DN ⁇ A-loaded, hydrogel isolated, cochleates
- the DNA/liposome mixture was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 ⁇ m. A CaCl 2 solution (100 mM) was added to the suspension to reach the final concentration of ImM.
- Step 1 Preparation of small unilamellar vesicles from dioleoylphosphatidylserine.
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-
- Step 1 Preparation of small unilamellar AmB-loaded vesicles from dioleoylphosphatidylserine.
- DOPS dioleoyl phosphatidylserine
- the dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml.
- the hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear yellow (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
- the liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran- 500,000 in a suspension of 2/1 v/v Dextran liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 ⁇ m. A ZnCl solution (100 mM) was added to suspension to reach the final concentration of 1 mM.
- An in vitro yeast susceptibility assay was performed comparing the inhibitory and lethal effects of AmB-cochleates, AmBisomes (liposomal formulation of AmB) and AmB/DMSO.
- Particle scavenging cells such as macrophage
- macrophage are the first line of defense against many microbial infections.
- many microbes, which induce severe human clinical infections have been shown to infect macrophage and avoid destruction.
- macrophage play an important role in the uptake of cochleates, via an endocytotic mechanism. Since macrophage also play an important role in the host defense and clearance of fungi and parasites, it is important to study the interaction between macrophage and cochleates.
- J774A.1 macrophage (M) were subcultured into a 96-well plate then incubated overnight. Following incubation, the macrophage were infected with CA at a ratio of 200:1, then subsequently AmBc, Fungizone or EC was added at the specified concentrations. Twenty four hours later, the cell cultures were observed and CFU's determined as described above.
- Example 17 Evaluation of tissue penetration of AmB after iv administration of amphotericin b hydrogel isolated cochleates
- Amphotericin B was eluted at a flow rate of 0.5 ml/min with 29% methanol, 30% acetonitrile and 41 % 2.5 mM EDTA and detected at 408 nm. The concentration of AmB was calculated with the help of an external standard curve.
- Example 18 Oral delivery of AmB mediated by hydrogel isolated cochleates loaded with AmB.
- Tissue and blood samples were processed as follows: tissues were diluted 1/20 or 1/10 by addition of extraction solvent (H 0 35%, methanol 10%, ethanol 55% w/w/w nv/v/v) and homogenized with an Ultra-Turrex® device. A 0.5 ml aliquot was taken, sonicated for 1 min
- Figure 10 shows the time profile of AmB in the tissues over a period f time of 24 hrs.
- mice received a 10 mg/kg/day oral multiple dose regime for ten days and one group was sacrificed 24 hrs after the last dose and the other group 20 days after the last dose received. At the predetermined time points mice were anesthetized, sacrificed and dissected for tissue collection. Tissues were processed as in single dose regime and AmB level determined by HPLC. Results from 24 h after the 10 th dose are depicted in Figure 11 and show that hydrogel isolated cochleates allow the delivery of AmB from the gastrointestinal tract at therapeutic levels.
- Example 19 Correlation between biodistribution in healthy and infected mice and the level of Candida albicans in tissue after oral administration
- Figure 12 shows the relationship between tissue levels of amphotericin B ( ⁇ g/g tissue
- orally administered AmB-cochleates were non-toxic even at the highest dose of 50 mg/kg (no lesions were found in kidneys, GI tract and other organs of mice given 10, 20 and 50 mg/kg of AmB-cochleates).
- This high dose 50mg/kg is equivalent to 100 times the lowest dose (0.5mg/kg) that showed 100% of survival in the Candida infected mouse model.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2358505A CA2358505C (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
EP00909961A EP1143933B1 (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
DE60035669T DE60035669T2 (en) | 1999-01-22 | 2000-01-24 | NEW CODES IN A HYDROGEL-ISOLATED COCHLEATE FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES |
DK00909961T DK1143933T3 (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel-isolated cochleate formulations, method of preparation and their use in delivering biologically relevant molecules |
JP2000594446A JP2002535267A (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, methods for their preparation and uses for the administration of biologically relevant molecules |
AU32133/00A AU3213300A (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
JP2001552865A JP2003529557A (en) | 2000-01-24 | 2001-01-24 | Cochleate formulations, methods for their preparation and uses for the administration of biologically relevant molecules |
AU31114/01A AU3111401A (en) | 2000-01-24 | 2001-01-24 | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
CA002397792A CA2397792A1 (en) | 2000-01-24 | 2001-01-24 | Cochleate formulations and their use for delivering biologically relevant molecules |
EP01903273A EP1259224A2 (en) | 2000-01-24 | 2001-01-24 | Cochleate formulations and their use for delivering biologically relevant molecules |
PCT/US2001/002299 WO2001052817A2 (en) | 2000-01-24 | 2001-01-24 | Cochleate formulations and their use for delivering biologically relevant molecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/235,400 | 1999-01-22 | ||
US09/235,400 US6153217A (en) | 1999-01-22 | 1999-01-22 | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000042989A2 true WO2000042989A2 (en) | 2000-07-27 |
WO2000042989A3 WO2000042989A3 (en) | 2000-11-30 |
Family
ID=22885334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001684 WO2000042989A2 (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
Country Status (12)
Country | Link |
---|---|
US (7) | US6153217A (en) |
EP (1) | EP1143933B1 (en) |
JP (1) | JP2002535267A (en) |
AT (1) | ATE367800T1 (en) |
AU (1) | AU3213300A (en) |
CA (1) | CA2358505C (en) |
CY (1) | CY1106916T1 (en) |
DE (1) | DE60035669T2 (en) |
DK (1) | DK1143933T3 (en) |
ES (1) | ES2290019T3 (en) |
PT (1) | PT1143933E (en) |
WO (1) | WO2000042989A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001052817A2 (en) * | 2000-01-24 | 2001-07-26 | Biodelivery Sciences, Inc. | Cochleate formulations and their use for delivering biologically relevant molecules |
US6592894B1 (en) | 1999-01-22 | 2003-07-15 | Biodelivery Sciences International, Inc. | Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
WO2004064805A1 (en) * | 2003-01-15 | 2004-08-05 | Biodelivery Sciences International, Inc. | Cochleate preparations of fragile nutrients |
WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
JP2005529086A (en) * | 2002-03-26 | 2005-09-29 | バイオデリバリー サイエンシズ インターナショナル インコーポレーティッド | A spiral made of purified soy phosphatidylserine |
EP2525778A2 (en) * | 2010-01-19 | 2012-11-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
EP2533762A1 (en) * | 2010-02-10 | 2012-12-19 | Biopelle Inc. | Retinol formulations and methods for their use |
US8546555B2 (en) | 2003-04-09 | 2013-10-01 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
US8642073B2 (en) | 2003-04-09 | 2014-02-04 | Biodelivery Sciences International, Inc. | Encochleation methods, cochleates and methods of use |
US8877242B2 (en) | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
US9408786B2 (en) | 2008-11-06 | 2016-08-09 | Biopelle, Inc. | Method for the treatment of skin |
CN108495619A (en) * | 2015-11-10 | 2018-09-04 | 儿研所儿童医学中心 | Echinomycin preparation and preparation method thereof and application method |
CN111053908A (en) * | 2013-05-03 | 2020-04-24 | 西莱克塔生物科技公司 | Administration combination for reducing undesired humoral immune responses |
US11779641B2 (en) | 2011-04-29 | 2023-10-10 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10154464B4 (en) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol |
WO2004012709A1 (en) * | 2002-08-06 | 2004-02-12 | Tuo Jin | Cochleates without metal cations as the bridging agents |
US20040092727A1 (en) * | 2002-11-13 | 2004-05-13 | Biopharm Solutions Inc. | Cochleates without metal cations as bridging agents |
JP3927887B2 (en) * | 2002-08-09 | 2007-06-13 | 本田技研工業株式会社 | Stator blade of axial compressor |
US8685428B2 (en) * | 2002-12-10 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Therapeutic composition and a method of coating implantable medical devices |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
DE10322439A1 (en) * | 2003-05-19 | 2004-12-09 | Bayer Ag | Method and device for determining the isomer composition in isocyanate production processes |
US20060188573A1 (en) * | 2003-06-10 | 2006-08-24 | Anna Imberg | Composite materials and particles |
SE527505C2 (en) * | 2003-06-10 | 2006-03-28 | Anna Imberg | Composite materials and particles |
KR101089534B1 (en) * | 2003-10-15 | 2011-12-05 | 가부시키가이샤 나노에그 | Method of controlling particle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method |
US20070258926A1 (en) * | 2003-10-15 | 2007-11-08 | Ltt Bio-Pharma Co., Ltd. | Composition containing retinoic acid nanoparticles coated with inorganic salt of polyvalent metal |
US20050244522A1 (en) * | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
US7494526B2 (en) * | 2004-07-14 | 2009-02-24 | Yavitz Edward Q | Plant protection and growth stimulation by nanoscalar particle folial delivery |
US20060040896A1 (en) * | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
US20070082030A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
US20070082029A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
US20070082115A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William Ronald Jr | Methods for inducing satiety, reducing food intake and reducing weight |
US20070082107A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
US20100178325A1 (en) * | 2006-08-23 | 2010-07-15 | Biodelivery Sciences International, Inc. | Amphiphilic nucleotide cochleate compositions and methods of using the same |
US20080085354A1 (en) * | 2006-10-06 | 2008-04-10 | Teresa Marie Paeschke | Controlled hydration of hydrocolloids |
EP2109459B1 (en) | 2006-12-15 | 2013-03-06 | National Research Council of Canada | Archaeal polar lipid aggregates for administration to animals |
US20090054374A1 (en) * | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
US8591225B2 (en) * | 2008-12-12 | 2013-11-26 | Align Technology, Inc. | Tooth movement measurement by automatic impression matching |
WO2009015183A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
US20090047336A1 (en) * | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
JP2010539245A (en) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | Drug carrier |
CN105126179B (en) | 2009-07-14 | 2018-09-25 | 波利皮得有限公司 | Sustained-release drug carrier composition |
WO2011016043A2 (en) | 2009-08-06 | 2011-02-10 | Technion Research & Development Foundation Ltd. | Antibiotic drug delivery and potentiation |
WO2011031018A2 (en) * | 2009-09-14 | 2011-03-17 | 한남대학교 산학협력단 | Water-soluble drug delivery system allowing slow release |
US20140220108A1 (en) * | 2011-05-05 | 2014-08-07 | University Of Medicine And Dentistry Of New Jersey | Cochleate compositions and methods of making and using same |
AU2012278832B2 (en) | 2011-07-06 | 2017-04-20 | The Regents Of The University Of California | Multiple-enzyme nanocomplexes |
WO2013033717A1 (en) | 2011-09-02 | 2013-03-07 | The Regents Of The University Of California | Enzyme responsive nanocapsules for protein delivery |
CA2872855C (en) | 2012-05-09 | 2021-07-27 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
WO2014151775A1 (en) * | 2013-03-15 | 2014-09-25 | Robert Bosch Gmbh | Heated garment and battery holster |
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
WO2016141203A1 (en) | 2015-03-03 | 2016-09-09 | Aquarius Biotechnologies, Inc. | Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent |
JP6991592B2 (en) * | 2016-07-12 | 2022-01-12 | マティナス バイオファーマ ナノテクノロジーズ,インコーポレーテッド | Treatment of co-created antifungal compounds and cryptococcal infections for central nervous system delivery |
KR101989789B1 (en) | 2017-11-30 | 2019-06-18 | (주) 에이치엔에이파마켐 | Cochleates using phosphatidylserine/anionic surfactant/calcium chloride |
WO2020066471A1 (en) * | 2018-09-28 | 2020-04-02 | 株式会社マンダム | Cosmetic |
US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
WO2024039729A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis |
WO2024039733A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840707A (en) * | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
US4990291A (en) * | 1986-04-15 | 1991-02-05 | The United States Of America As Represented By The Secretary Of The Navy | Method of making lipid tubules by a cooling process |
US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
JP2880800B2 (en) * | 1989-06-22 | 1999-04-12 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | Encapsulation method |
US5994318A (en) * | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
US5643574A (en) * | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
CA2246754C (en) | 1996-02-22 | 2002-10-22 | Raphael James Mannino | Cochleate delivery vehicles |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
-
1999
- 1999-01-22 US US09/235,400 patent/US6153217A/en not_active Expired - Fee Related
-
2000
- 2000-01-24 AU AU32133/00A patent/AU3213300A/en not_active Abandoned
- 2000-01-24 PT PT00909961T patent/PT1143933E/en unknown
- 2000-01-24 EP EP00909961A patent/EP1143933B1/en not_active Expired - Lifetime
- 2000-01-24 DE DE60035669T patent/DE60035669T2/en not_active Expired - Lifetime
- 2000-01-24 ES ES00909961T patent/ES2290019T3/en not_active Expired - Lifetime
- 2000-01-24 JP JP2000594446A patent/JP2002535267A/en active Pending
- 2000-01-24 AT AT00909961T patent/ATE367800T1/en active
- 2000-01-24 CA CA2358505A patent/CA2358505C/en not_active Expired - Fee Related
- 2000-01-24 WO PCT/US2000/001684 patent/WO2000042989A2/en active IP Right Grant
- 2000-01-24 DK DK00909961T patent/DK1143933T3/en active
- 2000-07-11 US US09/613,840 patent/US6592894B1/en not_active Expired - Lifetime
-
2003
- 2003-04-23 US US10/421,358 patent/US20030228355A1/en not_active Abandoned
-
2005
- 2005-01-18 US US11/040,615 patent/US20050186265A1/en not_active Abandoned
-
2007
- 2007-10-08 CY CY20071101285T patent/CY1106916T1/en unknown
-
2008
- 2008-04-23 US US12/148,942 patent/US20090028904A1/en not_active Abandoned
-
2012
- 2012-04-06 US US13/441,030 patent/US20120294901A1/en not_active Abandoned
-
2013
- 2013-12-31 US US14/145,268 patent/US20140220109A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840707A (en) * | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
Non-Patent Citations (3)
Title |
---|
ALBERTSSON P -A: "AQUEOUS POLYMER-PHASE SYSTEMS" 1986 , PARTITION OF CELL PARTICLES AND MACROMOLECULES,XX,XX, PAGE(S) 8-13,24-27,212-213 XP002030804 page 8, paragraph 1 - paragraph 2 page 212, paragraph 3 -page 213, paragraph 4 * |
PAPAHADJOPOULOS D ET AL: "COCHLEATE LIPID CYLINDERS FORMATION BY FUSION OF UNI LAMELLAR LIPID VESICLES" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 394, no. 3, 1975, pages 483-491, XP000938443 ISSN: 0006-3002 * |
ZARIF, L. ET AL: "Amphotericin B cochleates as a novel oral delivery system for the treatment of fungal infections" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1999), 26TH, 964-965 , XP002145322 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6592894B1 (en) | 1999-01-22 | 2003-07-15 | Biodelivery Sciences International, Inc. | Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
WO2001052817A3 (en) * | 2000-01-24 | 2002-02-21 | Biodelivery Sciences Inc | Cochleate formulations and their use for delivering biologically relevant molecules |
WO2001052817A2 (en) * | 2000-01-24 | 2001-07-26 | Biodelivery Sciences, Inc. | Cochleate formulations and their use for delivering biologically relevant molecules |
JP2005529086A (en) * | 2002-03-26 | 2005-09-29 | バイオデリバリー サイエンシズ インターナショナル インコーポレーティッド | A spiral made of purified soy phosphatidylserine |
WO2004064805A1 (en) * | 2003-01-15 | 2004-08-05 | Biodelivery Sciences International, Inc. | Cochleate preparations of fragile nutrients |
US8642073B2 (en) | 2003-04-09 | 2014-02-04 | Biodelivery Sciences International, Inc. | Encochleation methods, cochleates and methods of use |
US8546555B2 (en) | 2003-04-09 | 2013-10-01 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
US9974745B2 (en) | 2003-04-09 | 2018-05-22 | Rutgers, The State University Of New Jersey | Encochleation methods, cochleates and methods of use |
US9259392B2 (en) | 2003-04-09 | 2016-02-16 | Rutgers, The State University Of New Jersey | Cochleate compositions directed against expression of proteins |
WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
US8877242B2 (en) | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
US10682412B2 (en) | 2008-07-14 | 2020-06-16 | Polypid Ltd. | Sustained-release drug carrier composition |
US9408786B2 (en) | 2008-11-06 | 2016-08-09 | Biopelle, Inc. | Method for the treatment of skin |
EP2525778A2 (en) * | 2010-01-19 | 2012-11-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US8795726B2 (en) | 2010-01-19 | 2014-08-05 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
EP2525778A4 (en) * | 2010-01-19 | 2013-07-03 | Polypid Ltd | Sustained-release nucleic acid matrix compositions |
EP2533762A1 (en) * | 2010-02-10 | 2012-12-19 | Biopelle Inc. | Retinol formulations and methods for their use |
EP2533762A4 (en) * | 2010-02-10 | 2015-01-07 | Biopelle Inc | Retinol formulations and methods for their use |
US11779641B2 (en) | 2011-04-29 | 2023-10-10 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
CN111053908A (en) * | 2013-05-03 | 2020-04-24 | 西莱克塔生物科技公司 | Administration combination for reducing undesired humoral immune responses |
CN108495619A (en) * | 2015-11-10 | 2018-09-04 | 儿研所儿童医学中心 | Echinomycin preparation and preparation method thereof and application method |
EP3373910A4 (en) * | 2015-11-10 | 2019-06-12 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
US11116726B2 (en) | 2015-11-10 | 2021-09-14 | Childrens Research Institute, Childrens National Medical Center | Echinomycin formulation, method of making and method of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US6153217A (en) | 2000-11-28 |
EP1143933A2 (en) | 2001-10-17 |
DK1143933T3 (en) | 2007-11-26 |
US6592894B1 (en) | 2003-07-15 |
PT1143933E (en) | 2007-09-03 |
CY1106916T1 (en) | 2012-09-26 |
EP1143933B1 (en) | 2007-07-25 |
US20120294901A1 (en) | 2012-11-22 |
US20090028904A1 (en) | 2009-01-29 |
ATE367800T1 (en) | 2007-08-15 |
US20050186265A1 (en) | 2005-08-25 |
JP2002535267A (en) | 2002-10-22 |
US20030228355A1 (en) | 2003-12-11 |
WO2000042989A3 (en) | 2000-11-30 |
ES2290019T3 (en) | 2008-02-16 |
CA2358505C (en) | 2010-04-06 |
AU3213300A (en) | 2000-08-07 |
DE60035669D1 (en) | 2007-09-06 |
DE60035669T2 (en) | 2008-02-07 |
US20140220109A1 (en) | 2014-08-07 |
CA2358505A1 (en) | 2000-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1143933B1 (en) | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
Mehta et al. | Recent advances in inhalable liposomes for treatment of pulmonary diseases: concept to clinical stance | |
JP2958774B2 (en) | Improved preparation of amphotericin B liposomes | |
Zarif et al. | Cochleates: new lipid-based drug delivery system | |
CN106137967B (en) | Target the preparation and application of the dual modified liposome drug delivery system of glioma | |
Gulati et al. | Development of liposomal amphotericin B formulation | |
US11712407B2 (en) | Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same | |
AU3111401A (en) | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
US20030219473A1 (en) | Cochleates made with purified soy phosphatidylserine | |
WO1994028876A1 (en) | Liposome powders | |
AU2007200813B2 (en) | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
AU2004200967A1 (en) | Novel hydrogel isolated ochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
US20040092727A1 (en) | Cochleates without metal cations as bridging agents | |
Shivhare et al. | A Review on Liposomes as a Novel Drug Delivery System | |
US20040175417A1 (en) | Amphotericin B liposome preparation | |
AU2006202639A1 (en) | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
WO2004012709A1 (en) | Cochleates without metal cations as the bridging agents | |
Taylor et al. | Liposomes for drug delivery: developments and possibilities | |
CN114788813A (en) | Andrographolide freeze-dried liposome preparation for aerosol inhalation and preparation method and application thereof | |
GS et al. | Enhanced Tumor Targeting and Antitumor Activity of Gemcitabine Encapsulated Stealth Liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2358505 Country of ref document: CA Ref country code: CA Ref document number: 2358505 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 32133/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 594446 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000909961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000909961 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000909961 Country of ref document: EP |